Meet the Team

Subhamoy Chakraborty while studying microbiology in his undergraduate years in Kolkata, India, developed an interest in the field of Biochemistry which he followed during his MS in the Department of Biochemistry, University of Calcutta. Later after receiving the CSIR-JRF fellowship award from Govt. of India in 2015, he joined the lab of Dr. Sanjay Ghosh in the same department. In his doctoral research working in redox biology, he identified the axis of AMPK, SIRT1, and p53 as crucial regulators of cellular autophagy under nitro-oxidative stress.
He joined Dr. Triparna Sen’s lab at Icahn School of Medicine, Mount Sinai in June 2022. Subhamoy joined the Sen Lab in 2022 and since then been focused on identifying novel therapeutic strategies for small-cell lung cancer. He is specifically focused on identifying the mechanism of how DNA damage response pathways modulate anti-tumor immunity in this disease. During his tenure in the Sen Lab, he has already published a first-author paper in Clinical Cancer Research demonstrating the anti-tumor role of lurbinectedin in de novo and transformed small cell lung cancer preclinical models (PMID: 37382635). The overarching goal of his research is to improve the overall survival of patients with small-cell lung cancer.

Two truths and a lie:

1. Subhamoy has many of his poems published in little magazines.
2. Subhamoy has staged a performance as a lead actor in a group theater.
3. Subhamoy used to be a body-builder.

Utsav received his BS in microbiology from the University of Calcutta, and a MS in biotechnology at Bangalore University. He earned his Doctoral Degree in allied health and basic sciences (Specialization: cancer stem cell biology) from the Yenepoya Deemed to be University, Mangalore, India. During his PhD, Utsav received a Senior Research Fellowship from ICMR, Govt. of India. He also has received an opportunity to work as a vising scholar at CSIR-IICT, Hyderabad, India. He moved to Israel for his first post-doctoral fellowship at the Weizmann Institute of Science. He worked on TNBC biology and targeting TNBCs by a novel cell death process called ferroptosis.
Utsav joined the Sen lab in 2022 and has continued to work in ferroptosis biology as a novel therapeutic strategy to target non-small cell lung cancer. He has a specific interest in Stearoyl coenzyme A desaturase-1 which is a multitasker in cancer, metabolism, and ferroptosis (PMID: 37029018).

Two truths and a lie:

1. Utsav is an amazing cook.
2. Utsav plays the piano.
3. Utsav can sing like a pro.

Debdatta Halder has been a postdoctoral fellow in the Sen Lab since December 2023 and is currently working on unraveling lineage plasticity of cancer cells in lung cancer. She had been previously involved in dissecting the intratumor heterogeneity at single-cell level and understanding cytoskeletal mechano transduction during tumor progression. Debdatta received her PhD in Life Sciences from Indian Association for the Cultivation of Science (c/o Jadavpur University, India) in 2020. Debdatta likes to dream with eyes wide open and envisions a world without cancer.
Apart from her research, Debdatta is a quintessential Bengali, born and brought up in Kolkata (India) and thrives on everything Bengali. Music, food, nostalgia and books are her eternal friends.

Truths are backdated, let’s just share some lies.

1. Debdatta is not a disciple of the music maestro Pandit Ajoy Chakraborty
2. Debdatta hates NYC
3. Cancer cells are homogeneous and unchangeable

Dr. Yosuke Dotsu was working as a respiratory clinical physician in Japan for over 10 years, then went to graduate school to deepen his knowledge about lung cancer. He has spent time in graduate school developing T cell-based immunotherapy through metabolism, and he found a novel compound to regulate mitochondria, which led to T cell activation and significant antitumor effects even in low immunogenic tumor animal models.
Dr. Dotsu the Sen lab in April 2023. He is focused on identifying mechanisms of acquired resistance to targeted therapies in lung cancer. He is also focused on dissecting the molecular landscape of thoracic neuroendocrine tumors by performing multi-omic analysis of patient samples.

Vrinda is a Bioinformatician in the Bioinformatics for Next Generation Sequencing core (BiNGS) within the Tisch Cancer Institute (TCI), and she joined the Sen Lab in January 2024. She graduated with a master’s in Bioinformatics from Boston University. During her master’s she had completed an internship at Merck & Co., where she worked on Genome Annotation of a vaccine production strain. Prior to her master’s, she had worked as a Research Scientist at HealSeq Precision Medicine in Bangalore, India, where she primarily focused on RNA-Seq analysis, WES variant analysis and Boolean Modeling.